Bayer seeks Japanese marketing approval for finerenone to treat adult patients with chronic heart failure: Berlin Saturday, February 15, 2025, 14:00 Hrs [IST] Bayer announced the ...

An interview with Bayer's Bernardo Kanahuati, senior vice president, global head cardiorenal and product team lead, Kerendia, and Katja Rohwedder, senior medical affairs physician, global medical ...

【拜耳在中国和美国同时递交非奈利酮心力衰竭适应症上市申请】1月11日，拜耳宣布同时向中国国家药品监督管理局药品审评中心（CDE）和美国食品药品监督管理局（FDA）递交非奈利酮（finerenone）心力衰竭（心衰）适应症上市申请，用于左心室射血分数（LVEF）≥40%的成年心衰患者，即左心室射血分数轻度降低（HFmrEF）或左心室射血分数保留（HFpEF）的心衰患者 ...

A recent study from the FINEARTS-HF trial revealed that finerenone, which is an oral mineralocorticoid receptor antagonist, ...

由于其高患病率和发病率，心力衰竭（HF）仍然是对患者和医疗专业人员构成重大威胁的疾病。以下是 European Heart Journal（EHJ）整理的 2024 年发布的心衰领域 10 篇具有重大影响的研究。

Berlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), ...

Bayer announced the submission of a marketing authorization application to the European Medicines Agency (EMA), seeking approval in the EU for the use of finerenone in adult patients with HF with a ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients ...

Finerenone treatment vs placebo was associated with a reduced risk for new-onset diabetes by 24% among patients with HFmrEF or HFpEF.

Get ready for the Great American Smokeout on Nov. 21. Click here to download this infographic from CardioSmart to support conversations with patients. In the U.S., smoking contributes to one-third of ...

The first month of the year reinforces what we already know to be true: TCTMD readers have diverse interests, spanning the breadth of cardiology research and practice. Our most-read article of January ...